Phase I Study to Evaluate Bioavailability of Overencapsulated Celecoxib

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00729495
Recruitment Status : Completed
First Posted : August 7, 2008
Last Update Posted : May 14, 2009
Information provided by:

August 5, 2008
August 7, 2008
May 14, 2009
July 2008
August 2008   (Final data collection date for primary outcome measure)
Pharmacokinetics [ Time Frame: pre-dose, baseline and multiple times post-dose ]
Same as current
Complete list of historical versions of study NCT00729495 on Archive Site
Safety [ Time Frame: Throughout study ]
Same as current
Not Provided
Not Provided
Phase I Study to Evaluate Bioavailability of Overencapsulated Celecoxib
Phase I, Randomized, Open-Label, 2-Way Crossover Study to Evaluate Relative Bioavailability of Single Oral Dose of Celecoxib Administered as Marketed Product, or Overencapsulated Capsule in Healthy Volunteers
Phase I study designed to test the hypothesis that overencapsulated celecoxib 200 mg qd is bioequivalent to commercial celecoxib 200 mg qd. Approximately 90 healthy volunteers will be randomized to yield approximately 80 completers. The study is an open label, randomized, 2-way crossover with single dosing followed by a 7-day washout period between treatment arms
Not Provided
Phase 1
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Healthy Volunteer
Drug: celecoxib
dose form
Other Name: Celebrex
  • Active Comparator: 1
    marketed celecoxib
    Intervention: Drug: celecoxib
  • Experimental: 2
    overencapsulated celecoxib
    Intervention: Drug: celecoxib
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Same as current
October 2008
August 2008   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Healthy male and female subjects 18-55 yrs. of age (inclusive) at Screening Visit
  • Body Mass Index (BMI) of greater than or equal to 19 to less than or equal to 30 kg/m2 and weight of greater than or equal to 50 to less than or equal to 100 kg
  • Clinically normal physical exams and laboratory measurements

Exclusion Criteria:

  • Subject has received another investigational drug within 4 weeks preceeding this study or planning to participate in another study at any time during the period of this study
  • Any significant medical or psychiatric condition that could affect the interpretation of the PK data, or which otherwise would contraindicate participation in a clinical trial
  • Any GI disease, abnormality or gastric surgery that may interfere with gastric emptying, motility and drug absorption
  • Subject who has donated a unit of blood or plasma within 3 months prior to the Screening Visit
Sexes Eligible for Study: All
18 Years to 55 Years   (Adult)
Contact information is only displayed when the study is recruiting subjects
United States
Not Provided
Not Provided
Mark Sostek, MD, Medical Science Director, Development Project, AstraZeneca Pharmaceuticals
Study Director: Mark Sostek, MD AstraZeneca
Principal Investigator: Christopher Billings, DO Bio-Kinetic Clinical Applications, LLC
May 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP